Morningstar

Repligen Corp RGEN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$144.24 +0.30 (0.21%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier

Jay Lee

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems for both upstream and downstream processes, prepacked chromatography columns, proteins used in chromatography resins, and process analytic systems. Although Repligen is a relatively small player, we believe it is at the forefront of the innovation frontier. In the past 10 years, it has transformed from a company mostly known for its protein A ligands to one with a track record of launching new products with limited or no direct competition.

Read Full Report

Price vs Fair Value

View History
RGEN is trading at a LOCK|@rGNd#H premium.
Price
$144.24
Fair Value
qLg
Uncertainty
LOCK|ZN
1-Star Price
LOCK|G>
5-Star Price
<M&
Economic Moat
LOCK|^#zGZ
Capital Allocation
LOCK|%LXS>M<$

Bulls Say, Bears Say

Bulls

Repligen offers investors exposure to the rapidly growing and moatworthy bioprocessing industry and its market-leading product offerings.

Bears

Repligen’s adjusted EBITDA margins are around 20%, and it lags behind the industry average of high 20s.

Show More

News

View All

Trading Information

Previous Close Price
$143.94
Day Range
$141.84–145.19
52-Week Range
$100.99–175.77
Bid/Ask
$134.77 / $152.00
Shares Outstanding
56.41M
Market Cap
$8.14B
Volume/Avg
476,012 / 1M

Key Statistics

Price/Earnings (Normalized)
77.68
Price/Sales
10.37
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Core
Total Number of Employees
2,000
Website
https://www.repligen.com

Competitors

Valuation

View More
Metric
RGEN
DIM
SRT3
Price/Earnings (Normalized)
 77.6842.7969.77
Price/Book Value
 3.754.255.58
Price/Sales
 10.375.844.28
Price/Cash Flow
 44.6828.1921.46
Price/Earnings
RGEN
DIM
SRT3

Financial Strength

Metric
RGEN
DIM
SRT3
Quick Ratio
 7.420.530.46
Current Ratio
 9.201.030.91
Interest Coverage
 3.574.113.24
Quick Ratio
RGEN
DIM
SRT3

Profitability

Metric
RGEN
DIM
SRT3
Return on Assets (Normalized)
 3.50%3.42%2.61%
Return on Equity (Normalized)
 4.92%6.88%9.56%
Return on Invested Capital (Normalized)
 4.42%5.40%4.49%
Return on Assets
RGEN
DIM
SRT3

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
LOCK|B##!tKF$LOCK|P?$144B
 Becton Dickinson & Co
BDX
LOCK|!fqLOCK|FB&!$42B
 Medline Inc Ordinary Shares - Class A
MDLN
LOCK|b%Z>>VVLOCK|h&lh$35B
 Alcon Inc
ALC
LOCK|@DlGdx$LOCK|j>#>$33B
 ResMed Inc
RMD
LOCK|Hz<%phZlLOCK|y^&g$$30B
 West Pharmaceutical Services Inc
WST
LOCK|t!byJp>^LOCK|H&$25B
 The Cooper Companies Inc
COO
LOCK|##wC@gLOCK|Tf@V$14B
 Solventum Corp
SOLV
LOCK|pSF@C>LOCK|?C$13B
 Align Technology Inc
ALGN
LOCK|f$SbH$MLOCK|tcyQ$13B
 Baxter International Inc
BAX
LOCK|kpLOCK|jlQ>$12B

Sponsor Center